Stockreport

DS-9606 Shows Promising Preliminary Clinical Activity in Patients with Advanced Solid Tumors

DAIICHI SANKYO S/ADR  (DSNKY) 
PDF First presentation of clinical data from Daiichi Sankyo’s second ADC platformPatient enrollment into dose escalation continues to determine recommended dose of DS-9606 f [Read more]